Tolero Pharmaceuticals has pocketed a second tranche of its Series B funding round, netting $22.4 million in total as it prepares to take its expirimental marrow cancer treatment into late-stage development.
Researchers at Imperial College London have created an artificial cell with separate compartments that can communicate with one another via chemical reactions, much the way, for instance, the nucleus would communicate with other parts of the cell.
AstraZeneca's ovarian cancer-treating olaparib may also have a beneficial effect on prostate cancer, researchers said, potentially increasing the value of a key drug in the company's self-appraised $12 billion oncology pipeline.
Maryland's Technology Development Corp. is dishing out funds for startups and early stage digital health companies. Overall, 15 med tech companies received a total of $1.5 million.
Regeneron is pouring more money than ever into its well-respected R&D operation, spending big on a cadre of late-stage candidates the Big Biotech believes can outshine its blockbuster eye treatment.
With small but prestigious contributions from the scientific community, SQZ Biotech is looking to launch its CellSqueeze platform to be used in commercial applications.
In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as it works to build a portfolio of such treatments.
Medical device startup Force Impact Technologies designed a mouthguard that can provide real-time alerts on concussions during high-impact activities to coaches and medical professionals.
With generic and branded rivals inching up on AstraZeneca's blockbuster respiratory drug Symbicort, the pharma giant has a game plan locked, loaded and ready to go. The company sealed the deal for Almirall's respiratory portfolio, inheriting a couple of marketed drugs to expand its current offerings and a list of medications currently under development.
Bristol-Myers Squibb has grabbed an option on an early-stage program for idiopathic pulmonary fibrosis this morning, forging a deal to potentially buy out Denmark's Galecto Biotech for up to $444 million--if the drug pans out in the clinic.